Company Overview of Miltenyi Biotec GmbH
Miltenyi Biotec GmbH develops and manufactures cell labeling reagents, cell separation and analysis devices, and systems for clinical applications globally. Its products include MACS sample preparation, MACS cell separation, MACS flow cytometry, MACS cell culture and stimulation, and MACS molecular; research areas include immunology, stem cell research, neuroscience, and cancer research; and clinical applications include clinical development, CliniMACS system, MACS GMP products, CryoMACS freezing products, TheraSorb, graft engineering, immunotherapy, tissue regeneration, and freezing products. The company was founded in 1989 and is based in Bergisch Gladbach, Germany with additional offices ...
Bergisch Gladbach, 51429
Founded in 1989
Key Executives for Miltenyi Biotec GmbH
Global Head Clinical Products
General Manager of Gangnam District for Seoul
Compensation as of Fiscal Year 2015.
Miltenyi Biotec GmbH Key Developments
TotipotentRX Signs Multi-Year Distribution Agreement with Miltenyi Biotec GmbH for Clinical Product Sales Throughout India
Oct 28 15
Cesca Therapeutics Inc. announced that its subsidiary, TotipotentRX, has signed a multi-year distribution agreement with Miltenyi Biotec GmbH (Germany) for clinical product sales throughout India. As part of the agreement, TotipotentRX's advanced haploidentical transplant program will incorporate Miltenyi Biotec's CliniMACS® Cell Separation System, used for selecting beneficial cells or depleting donor immune cells from grafts that may interfere with engraftment in preparation for bone marrow transplantation. TotipotentRX provides specialized clinical cell manufacturing technology, services and expertise to major hospital networks in the rapidly growing Indian transplant market, including its exclusive agreement with Fortis Healthcare. With this agreement Miltenyi reinforces Cesca's leadership position while strategically positioning itself for future growth in Asia. Miltenyi Biotec is a global leader and pioneer in delivering comprehensive cell-based reagent/equipment systems to biomedical and clinical researchers. The CliniMACS Cell Separation System is based on proven magnetic cell separation methodology, the renowned MACS® Technology, enabling consistent generation of cellular products for a wide range of clinical applications. Many graft engineering haploidentical transplant protocols employ the use of Miltenyi Biotec products to deplete donor T and B lymphocytes prior to transplantation. Ex-vivo depletion of these cells can greatly reduce the risk of life-threatening Graft versus Host Disease (GVHD), a significant threat to the use of partially matched relatives as donors (haploidentical transplantation) frequently used in India. GVHD occurs when the donor's immune cells attack the recipient's tissue, causing serious damage to major tissues and organs throughout the body.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries